Last checked at 22 Sep 2022 17:59
Iconic Labs PLC
22 September 2022
Iconic Labs Plc - In Administration ("Iconic Labs" or the "Company")
Notice of Results of Creditors Meeting and General Meeting of Shareholders
Iconic Labs Plc (LSE:ICON hereby advises that it held a general meeting ("GM") earlier today.
The CVA Proposal was approved by the requisite majorities of the creditors at a meeting of the creditors held today at 11am.
At a meeting of the shareholders of the Company, held today at 2.00pm, all resolutions were duly passed on a poll vote.
Details of the proxy voting are shown in the table below.
| Votes For | % | Votes Against | % | Votes Total | Votes Withheld |
Ordinary resolutions: | ||||||
(1) Approval of the Company Voluntary Arrangement ("CVA"). | 10,009,834,608
| 97.49 | 257,331,813
|
2.51
| 10,267,166,421 |
48,068,796
|
(2) To empower the directors to generally allot relevant equity securities in respect of the CVA | 10,240,735,765
|
99.74
| 26,430,656
|
0.26
| 10,267,166,421
|
48,068,796
|
(3) To empower the directors to generally allot relevant equity securities to promote the success of the Company | 10,240,225,765
|
99.74
| 26,430,656
|
0.26
| 10,266,656,421
|
48,578,796
|
Special resolutions: | ||||||
(4) Subject to the passing of Resolution 2, to disapply the pre-emptive rights in respect of the relevant equity securities to be allotted in respect of CVA Proposal. | 10,009,324,608
|
97.49
| 257,331,813
|
2.51
| 10,266,656,421
|
48,578,796
|
(5) Subject to the passing of Resolution 3, to disapply the pre-emptive rights in respect of the relevant equity securities to be allotted to promote the success of the Company. | 10,240,225,765
|
99.74
| 26,430,656
|
0.26
| 10,266,656,421
|
48,578,796
|
The full text of each of the resolutions is set out in the Notice of AGM, available on the Company's website (www.iconiclabs.co.uk).
Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
For further information, please visit the Company's website www.iconiclabs.co.uk or contact the Company via ir@iconiclabs.co.uk.
END